NCT05974007View on ClinicalTrials.gov

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

RecruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

June 1, 2026

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Neoadjuvant immunochemotherapy

Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery

DRUG

Neoadjuvant chemotherapy

Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER